Search

Your search keyword '"Peperzak, Victor"' showing total 202 results
Start Over Author "Peperzak, Victor"
202 results on '"Peperzak, Victor"'

2. Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model

Author

MS Hematologie, Infection & Immunity, Cancer, CTI Peperzak, Regenerative Medicine and Stem Cells, van Nieuwenhuijzen, Niels, Cuenca, Marta, Abbink, Leonie, Jak, Margot, Peperzak, Victor, Minnema, Monique C, MS Hematologie, Infection & Immunity, Cancer, CTI Peperzak, Regenerative Medicine and Stem Cells, van Nieuwenhuijzen, Niels, Cuenca, Marta, Abbink, Leonie, Jak, Margot, Peperzak, Victor, and Minnema, Monique C

Published
2024

4. Bridging the gap between scientific discoveries and clinical application at the Utrecht Science Park

Author

Peperzak, Victor, Coquet, Jonathan M., Peperzak, Victor, and Coquet, Jonathan M.

Abstract

Associate Professor Victor Peperzak from the University Medical Center (UMC) Utrecht in the Netherlands discusses the opportunities and challenges of building a research group in the Netherlands. Victor highlights the scientific strengths of UMC Utrecht in juxtaposition with other universities and centers around the Netherlands, and highlights the collaborative nature of the Dutch research scene.

Published
2024

9. Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐XL in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients

Author

Beltrán‐Visiedo, Manuel, primary, Jiménez‐Alduán, Nelia, additional, Díez, Rosana, additional, Cuenca, Marta, additional, Benedi, Andrea, additional, Serrano‐Del Valle, Alfonso, additional, Azaceta, Gemma, additional, Palomera, Luis, additional, Peperzak, Victor, additional, Anel, Alberto, additional, Naval, Javier, additional, and Marzo, Isabel, additional

Published
2023
Full Text
View/download PDF

12. Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐XL in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients.

Author

Beltrán‐Visiedo, Manuel, Jiménez‐Alduán, Nelia, Díez, Rosana, Cuenca, Marta, Benedi, Andrea, Serrano‐Del Valle, Alfonso, Azaceta, Gemma, Palomera, Luis, Peperzak, Victor, Anel, Alberto, Naval, Javier, and Marzo, Isabel

Abstract

A better understanding of multiple myeloma (MM) biology has led to the development of novel therapies. However, MM is still an incurable disease and new pharmacological strategies are needed. Dinaciclib, a multiple cyclin‐dependent kinase (CDK) inhibitor, which inhibits CDK1, 2, 5 and 9, displays significant antimyeloma activity as found in phase II clinical trials. In this study, we have explored the mechanism of dinaciclib‐induced death and evaluated its enhancement by different BH3 mimetics in MM cell lines as well as in plasma cells from MM patients. Our results indicate a synergistic effect of dinaciclib‐based combinations with B‐cell lymphoma 2 or B‐cell lymphoma extra‐large inhibitors, especially in MM cell lines with partial dependence on myeloid cell leukemia sequence 1 (MCL‐1). Simultaneous treatment with dinaciclib and BH3 mimetics ABT‐199 or A‐1155463 additionally showed a synergistic effect in plasma cells from MM patients, ex vivo. Altered MM cytogenetics did not affect dinaciclib response ex vivo, alone or in combined treatment, suggesting that these combinations could be a suitable therapeutic option for patients bearing cytogenetic alterations and poor prognosis. This work also opens the possibility to explore cyclin‐dependent kinase 9 inhibition as a targeted therapy in MM patients overexpressing or with high dependence on MCL‐1. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Serpin B9 controls tumor cell killing by CAR T cells

Author

Kimman, Thomas, primary, Slomp, Anne, additional, Martens, Anne, additional, Grabherr, Sarah, additional, Li, Shuang, additional, van Diest, Eline, additional, Meeldijk, Jan, additional, Kuball, Jurgen, additional, Minnema, Monique C, additional, Eldering, Eric, additional, Bovenschen, Niels, additional, Sebestyén, Zsolt, additional, and Peperzak, Victor, additional

Published
2023
Full Text
View/download PDF

16. Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma

Author

Unit Opleiding Aios, Infection & Immunity, CTI Boes, PMC Medisch specialisten, Zorg en O&O, Child Health, CTI Peperzak, Cancer, Greve, Patrick, Beishuizen, Auke, Hagleitner, Melanie, Loeffen, Jan, Veening, Margreet, Boes, Marianne, Peperzak, Victor, Diez, Claudius, Meyer-Wentrup, Friederike, Unit Opleiding Aios, Infection & Immunity, CTI Boes, PMC Medisch specialisten, Zorg en O&O, Child Health, CTI Peperzak, Cancer, Greve, Patrick, Beishuizen, Auke, Hagleitner, Melanie, Loeffen, Jan, Veening, Margreet, Boes, Marianne, Peperzak, Victor, Diez, Claudius, and Meyer-Wentrup, Friederike

Published
2023

17. Serpin B9 controls tumor cell killing by CAR T cells

Author

CTI Peperzak, Cancer, Infection & Immunity, Pathologie patiënten zorg, Pathologie Research, CTI Kuball, MS Hematologie, Regenerative Medicine and Stem Cells, Pathologie Groep Bovenschen, Kimman, Thomas, Slomp, Anne, Martens, Anne, Grabherr, Sarah, Li, Shuang, van Diest, Eline, Meeldijk, Jan, Kuball, Jurgen, Minnema, Monique C., Eldering, Eric, Bovenschen, Niels, Sebestyén, Zsolt, Peperzak, Victor, CTI Peperzak, Cancer, Infection & Immunity, Pathologie patiënten zorg, Pathologie Research, CTI Kuball, MS Hematologie, Regenerative Medicine and Stem Cells, Pathologie Groep Bovenschen, Kimman, Thomas, Slomp, Anne, Martens, Anne, Grabherr, Sarah, Li, Shuang, van Diest, Eline, Meeldijk, Jan, Kuball, Jurgen, Minnema, Monique C., Eldering, Eric, Bovenschen, Niels, Sebestyén, Zsolt, and Peperzak, Victor

Published
2023

18. Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma

Author

CTI Peperzak, MS Hematologie, Cancer, Infection & Immunity, CMM Groep Maurice, Regenerative Medicine and Stem Cells, Spaan, Ingrid, van Nieuwenhuijzen, Niels, Kimman, Thomas, Rockx-Brouwer, Dedeke, Tieland, Ralph G, Maurice, Madelon, Minnema, Monique C, Raymakers, Reinier, Peperzak, Victor, CTI Peperzak, MS Hematologie, Cancer, Infection & Immunity, CMM Groep Maurice, Regenerative Medicine and Stem Cells, Spaan, Ingrid, van Nieuwenhuijzen, Niels, Kimman, Thomas, Rockx-Brouwer, Dedeke, Tieland, Ralph G, Maurice, Madelon, Minnema, Monique C, Raymakers, Reinier, and Peperzak, Victor

Published
2023

20. Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition

Author

Cancer, CTI Peperzak, MS Hematologie, CDL Patiëntenzorg MI, Infection & Immunity, Regenerative Medicine and Stem Cells, Cuenca, Marta, Van Nieuwenhuijzen, Niels, Moesbergen, Laura M, Bloem, Andries, Minnema, Monique C, Peperzak, Victor, Cancer, CTI Peperzak, MS Hematologie, CDL Patiëntenzorg MI, Infection & Immunity, Regenerative Medicine and Stem Cells, Cuenca, Marta, Van Nieuwenhuijzen, Niels, Moesbergen, Laura M, Bloem, Andries, Minnema, Monique C, and Peperzak, Victor

Published
2022

30. Inhibitory pattern recognition receptors

Author

CTI Meyaard, Infection & Immunity, CTI Peperzak, Cancer, CTI, Rumpret, Matevž, von Richthofen, Helen J, Peperzak, Victor, Meyaard, Linde, CTI Meyaard, Infection & Immunity, CTI Peperzak, Cancer, CTI, Rumpret, Matevž, von Richthofen, Helen J, Peperzak, Victor, and Meyaard, Linde

Published
2021

32. Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma

Author

CTI Peperzak, Cancer, CTI Van der Vlist, Infection & Immunity, MS Hematologie, Regenerative Medicine and Stem Cells, Spaan, Ingrid, Timmerman, Laura M, Kimman, Thomas, Slomp, Anne, Cuenca, Marta, van Nieuwenhuijzen, Niels, Moesbergen, Laura M, Minnema, Monique C, Raymakers, Reinier A, Peperzak, Victor, CTI Peperzak, Cancer, CTI Van der Vlist, Infection & Immunity, MS Hematologie, Regenerative Medicine and Stem Cells, Spaan, Ingrid, Timmerman, Laura M, Kimman, Thomas, Slomp, Anne, Cuenca, Marta, van Nieuwenhuijzen, Niels, Moesbergen, Laura M, Minnema, Monique C, Raymakers, Reinier A, and Peperzak, Victor

Published
2021

33. Upcoming immunotherapeutic combinations for B-cell lymphoma

Author

CTI Boes, Immuno/reuma onderzoek 2 (Boes), Onderzoek, Child Health, Infection & Immunity, Cancer, CTI Peperzak, Greve, Patrick, Meyer Wentrup, Friederike, Peperzak, Victor, Boes, Marianne, CTI Boes, Immuno/reuma onderzoek 2 (Boes), Onderzoek, Child Health, Infection & Immunity, Cancer, CTI Peperzak, Greve, Patrick, Meyer Wentrup, Friederike, Peperzak, Victor, and Boes, Marianne

Published
2021

34. Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, CTI Peperzak, Slomp, Anne, Moesbergen, Laura M, Eldering, Eric, Kersten, Marie José, Minnema, Monique C, Peperzak, Victor, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, CTI Peperzak, Slomp, Anne, Moesbergen, Laura M, Eldering, Eric, Kersten, Marie José, Minnema, Monique C, and Peperzak, Victor

Published
2021

35. CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production

Author

Peperzak, Victor, Xiao, Yanling, Veraar, Elise A.M., and Borst, Jannie

Subjects
Gene expression -- Physiological aspects -- Genetic aspects -- Health aspects, T cells -- Genetic aspects -- Health aspects -- Physiological aspects, Autocrine mechanisms -- Genetic aspects -- Health aspects -- Physiological aspects, Interleukin-2 -- Health aspects -- Physiological aspects, Health care industry
Abstract

Immunity to infections relies on clonal expansion of [CD8.sup.+] T cells, their maintenance as effector CTLs, and their selection into a memory population. These processes rely on delivery of survival signals to activated [CD8.sup.+] T cells. We here reveal the mechanism by which costimulatory CD27-CD70 interactions sustain survival of [CD8.sup.+] effector T cells in infected tissue. By unbiased genome-wide gene expression analysis, we identified the Il2 gene as the most prominent CD27 target gene in murine [CD8.sup.+] T cells. In vitro, CD27 directed IL-2 expression and promoted clonal expansion of primed [CD8.sup.+] T cells exclusively by IL-2-dependent survival signaling. In mice intranasally infected with influenza virus, [Cd27.sup.[-/-]] [CD8.sup.+] effector T cells displayed reduced IL-2 production, accompanied by impaired accumulation in lymphoid organs and in the lungs, which constitute the tissue effector site. Reconstitution of [Cd27.sup.[-/-]] [CD8.sup.+] T cells with the IL2 gene restored their accumulation to wild-type levels in the lungs, but it did not rescue their accumulation in lymphoid organs. Competition experiments showed that the IL-2 produced under the control of CD27 supported effector [CD8.sup.+] T cell survival in the lungs in an autocrine manner. We conclude that CD27 signaling directs the IL-2 production that is reportedly essential to sustain survival of virus-specific CTLs in nonlymphoid tissue., Introduction Control of T cell survival is essential for an adequate immune response (1). Throughout their life span, T cells find themselves in different cellular niches, where they may be [...]

Published
2010
Full Text
View/download PDF

36. Endochondral Bone Regeneration by Non-autologous Mesenchymal Stem Cells

Author

MKA/BT Onderzoek, Other research (not in main researchprogram), CTI Peperzak, Cancer, MS Orthopaedie Algemeen, Infection & Immunity, Zorgeenheid MKA/BT Medisch, Orthopaedie Onderzoek, Regenerative Medicine and Stem Cells, Longoni, Alessia, Pennings, I, Cuenca Lopera, Marta, van Rijen, M H P, Peperzak, Victor, Rosenberg, A J W P, Levato, Riccardo, Gawlitta, Debby, MKA/BT Onderzoek, Other research (not in main researchprogram), CTI Peperzak, Cancer, MS Orthopaedie Algemeen, Infection & Immunity, Zorgeenheid MKA/BT Medisch, Orthopaedie Onderzoek, Regenerative Medicine and Stem Cells, Longoni, Alessia, Pennings, I, Cuenca Lopera, Marta, van Rijen, M H P, Peperzak, Victor, Rosenberg, A J W P, Levato, Riccardo, and Gawlitta, Debby

Published
2020

40. DNA-binding of the Tet-transactivator curtails antigen-induced lymphocyte activation in mice

Author

Ottina, Eleonora, Peperzak, Victor, Schoeler, Katia, Carrington, Emma, Sgonc, Roswitha, Pellegrini, Marc, Preston, Simon, Herold, Marco J., Strasser, Andreas, and Villunger, Andreas

Subjects
Male, Science, Mice, Transgenic, Tetracycline, Lymphocyte Activation, Article, Mice, Inbred C57BL, Repressor Proteins, Mice, Trans-Activators, Animals, lcsh:Q, Female, Lymphocytes, lcsh:Science, Promoter Regions, Genetic
Abstract

The Tet-On/Off system for conditional transgene expression constitutes state-of-the-art technology to study gene function by facilitating inducible expression in a timed and reversible manner. Several studies documented the suitability and versatility of this system to trace lymphocyte fate and to conditionally express oncogenes or silence tumour suppressor genes in vivo. Here, we show that expression of the tetracycline/doxycycline-controlled Tet-transactivator, while tolerated well during development and in immunologically unchallenged animals, impairs the expansion of antigen-stimulated T and B cells and thereby curtails adaptive immune responses in vivo. Transactivator-mediated cytotoxicity depends on DNA binding, but can be overcome by BCL2 overexpression, suggesting that apoptosis induction upon lymphocyte activation limits cellular and humoral immune responses. Our findings suggest a possible system-intrinsic biological bias of the Tet-On/Off system in vivo that will favour the outgrowth of apoptosis resistant clones, thus possibly confounding data published using such systems., Tet-transactivators are used for direct regulation of gene expression, RNA interference and for CRISPR/Cas9-based systems. Here the authors show that DNA-bound Tet-transactivators can induce cell death in antigen-activated lymphocytes in vivo, putting into question the use of, and in vivo data generated with, these molecular tools.

Published
2017

41. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting

Author

CTI Peperzak, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Slomp, Anne, Moesbergen, Laura M, Gong, Jia-Nan, Cuenca, Marta, von dem Borne, Peter A, Sonneveld, Pieter, Huang, David C S, Minnema, Monique C, Peperzak, Victor, CTI Peperzak, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Slomp, Anne, Moesbergen, Laura M, Gong, Jia-Nan, Cuenca, Marta, von dem Borne, Peter A, Sonneveld, Pieter, Huang, David C S, Minnema, Monique C, and Peperzak, Victor

Published
2019

48. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells

Author

MS Hematologie, CTI Peperzak, Infection & Immunity, Regenerative Medicine and Stem Cells, van Nieuwenhuijzen, Niels, Spaan, Ingrid, Raymakers, Reinier, Peperzak, Victor, MS Hematologie, CTI Peperzak, Infection & Immunity, Regenerative Medicine and Stem Cells, van Nieuwenhuijzen, Niels, Spaan, Ingrid, Raymakers, Reinier, and Peperzak, Victor

Published
2018

49. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential

Author

CTI Peperzak, Infection & Immunity, MS Hematologie, Regenerative Medicine and Stem Cells, Spaan, Ingrid, Raymakers, Reinier A, van de Stolpe, Anja, Peperzak, Victor, CTI Peperzak, Infection & Immunity, MS Hematologie, Regenerative Medicine and Stem Cells, Spaan, Ingrid, Raymakers, Reinier A, van de Stolpe, Anja, and Peperzak, Victor

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results